Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Kurita Water Industries Ltd. (栗田工業株式会社 Kurita Kōgyō Kabushiki-gaisha) is a Japanese manufacturer, providing water treatment chemicals and facilities as well as process treatment chemicals. During the 50´s Kurita Water Industries expanded the portfolio and started with the water treatment facilities business, chemical cleaning business (Kurita Engineering Co., Ltd.) and maintenance services. In her second decade, the 60´s, Kurita Water Industries entered the process treatment market, especially in the pulp and paper, petrochemical and steel industries. Since the mid of the 70´s up to now, Kurita Water Industries established 14 overseas subsidiaries and affiliates. Since 2003 Kurita Water Industries is listed in the Nature Stock Index (NAI = Natur-Aktien-Index).

Kedrion SpA is a holding company, which engages in the production and distribution of plasma-derived therapeutic products for the treatment of hemophilia and immune system deficiencies. It offers standard intravenous immunoglobulin, human albumin solution, human rabies immunoglobulin, prothrombin complex concentrate, and fibrin sealant. Its products include Kedrab, Gammaked, Uman Complex, Kolfib, and Uman Albumin. The company was founded by Guelfo Marcucci in 2001 and is headquartered in Barga, Italy.

Aqua-Chem is the leader in providing Global Water Solutions. They develop innovative and comprehensive water solutions for the Military, Pharmaceutical, Offshore Oil and Gas, Industrials, Bottled Water, Commercial Marine, and Micro-utilities markets. They build water processing systems with custom engineering and cutting edge technology; using high quality in-house manufacturing, superior components, and the highest quality customer service. Aqua-Chem, along with their Matrix and Specific Equipment product lines, provides complete water solutions in the markets they serve around the globe. They pride themselves on the fact that Aqua-Chem is the premiere water treatment and micro-utility company in the world. Water Solutions begin and end with Aqua-Chem.

Dionex Corporation develops, manufactures, sells, and services chromatography and extraction systems for separating, isolating, and identifying the components of chemical mixtures. Their continuing leadership in chromatography helps us create powerful solutions to increase productivity for the industries that shape the world. Their solutions are used by the environmental, life sciences, pharmaceutical, food and beverage, chemicals, power generation, and electronics industries.

O C P SAS is a private company headquartered in Saint Ouen, France. The firm provides fund management services.

Manufactures aluminium products

Established in 1996, Orochem Technologies Inc. started as a Biotech and Chromatography company to manufacture unique Sample Prep Technology Products for the Bioanalysis, Drug Discovery, and the Genomics and Proteomics markets. Backed with unique expertise in high throughput formats, membranes and surface chemistries, Orochem was one of the first companies to translate the concept of pre-filters from single to high throughput formats, a concept now widely implemented for sample prep plates in the biotech and analytical markets. In the year 2001 Orochem manufactured the first commercially available Protein Crash and Precipitation 96-well plate for Bioanalytical processes. By the year 2006, with the acquisition of Column Engineering Inc, Orochem evolved to become a “full-service” provider for silica manufacturing utilized for analytical and preparatory chromatography. Orochem invests heavily into R&D in-house and owns strong intellectual property in stationary phases for achiral and Chiral Chromatography.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

Founded in 1980, Unigene is a publicly traded biopharmaceutical company with corporate offices, an R&D facility and a state-of-the-art recombinant manufacturing facility in New Jersey. There broad experience in molecular biology, protein chemistry, immunology and formulation development combined with there entrepreneurial spirit and innovation have led to the development of proprietary technologies, protected by a strong patent portfolio, enabling the commercialization of peptide drugs.

Beijing Longke Ark Bioengineering Technology Co., Ltd., established on 2001-07-23, Business scope includes technology development,technical consulting,Technical Services,technology transfer.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Rohm and Haas Company is a manufacturer of speciality chemicals for end use markets such as building and construction, electronic devices, packaging, household and personal care products. Headquartered in Philadelphia, the company is organised into three business groups of Specialty Materials, Performance Materials and Electronic Materials, and also has two stand-alone businesses of Powder Coatings and Salt. Formerly a Fortune 500 Company, Rohm and Haas employs more than 17,000 people in 27 countries, with its last sales revenue reported as an independent company at US$8.9 billion. Dow Chemical Company bought Rohm and Haas for $15 billion in 2009.

Zhejiang Huapu Xinchuang Technology Co., Ltd., established on 2011-12-21, Business scope includes separation materials(non-hazardous,toxic chemicals),Chromatographic column,Solid phase extraction column,separation equipment,Analytical Instrument Manufacturing,Sales,technology development,technology transfer,technical consulting,Technical Services;Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Octapharma is a privately-owned global human proteins manufacturer headquartered in Lachen, Switzerland. Since its establishment in 1983 the company has been dedicated to improving the lives of patients. Octapharma was founded in 1983 on the fundamental principle of improving the lives of patients. Since then we have remained focused on our collective responsibility for the trust instilled in us by physicians and patients worldwide. In 2012, the Octapharma Board identified the core strategic pillars which will lead to the achievement of the organization’s ambitious long term goals.

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

Part of China Animal Healthcare Ltd., Inner Mongolia Bigvet Biotech Co., Ltd. is a company headquartered in China. The firm engages in researching, developing, manufacturing and distributing of biological products.

Hankook Pharm Co., Ltd. (doing business as Korea Pharmaceuticals Corp.) is a South Korean private company. The firm manufactures pharmaceuticals.